SAN FRANCISCO -
- 12-Month Data Also Demonstrate Significant Reduction in Left Ventricular Volumes
Twelve-month data from EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) study high-risk registry arm presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco show that high risk patients with functional mitral regurgitation (MR) following valve repair with the MitraClip(R) system showed a reduction in mitral annular dimension, improvement in heart function and a reduction in hospitalization for congestive heart failure.
The data were presented today by Saibal Kar, M.D., director of interventional cardiac research at Cedars-Sinai Medical Center, Los Angeles, CA and the lead enrolling investigator of the EVEREST II trial. The EVEREST II study was designed to evaluate the MitraClip(R) system for the treatment of MR.
This data included 34 patients from the high-risk registry with moderate-to-severe (3+) or severe (4+) functional mitral regurgitation who received a MitraClip(R) device and had matched core laboratory echocardiographic data at baseline and 12 months. Results included a mean MR grade reduction from 3.2+/-0.5 at baseline to 1.8+/-0.9 at 12 months. In addition to the reduction of MR, there was significant reduction in the systolic and diastolic septo-lateral mitral annular diameter as well as a significant reduction in left ventricular end diastolic and systolic volumes. Left ventricular ejection fraction (LV EF) did not change significantly from baseline, while forward stroke volume (FSV) improved, indicating improved cardiac efficiency. Results were as follows:
Baseline and 1 year echocardiographic results
Baseline 1 year p-value ——– —— ——- MR (n=34) 3.2+/-0.5 1.8+/-0.9 <0.0001 -------- ------- ------- ------- Septo-lateral mitral annular diameter (systolic) (cm) (n=33) 3.2 +/- 0.4 3.0 +/- 0.3 0.0072 ------------------------------------- ----------- ----------- ------ Septo-lateral mitral annular diameter (diastolic) (cm) (n=33) 3.8 +/- 0.3 3.6 +/- 0.3 <0.0001 ------------------------------------- ----------- ----------- ------- LV EF (percentage) (n=34) 47 +/- 11 44 +/- 11 NS ------------------------ ------- ------- ---- FSV (ml) (n=33) 51 +/- 13 55 +/- 15 0.06 -------------- ------- ------- ---- LVEDV (ml) (n = 34) 192 +/- 46 153 +/- 44 <0.0001 ------------------ -------- -------- ------- LVESV (ml) (n = 34) 103 +/- 37 87 +/- 35 0.0002 ------------------- -------- ------- ------- LVID-d (cm) (n = 34) 6.0 +/- 0.6 5.6 +/- 0.7 <0.0001 ------------------- --------- --------- ------- LVID-s (cm) (n = 34) 4.5 +/- 0.9 4.3 +/- 0.9 NS ------------------- --------- --------- ----
“We were pleased to see that in addition to a reduction in MR, patients had significant reductions in left ventricle size and mitral annual diameter we believe contributes to an improved quality of life,” said Dr. Kar. “With this therapy, we have been able to expand the options available to selected patients who are at high risk for more invasive treatments, and help them to avoid the risks associated with surgery. We look forward to validating these important findings with ongoing studies.”
The MitraClip(R) system is the first commercially available treatment option for non-surgical mitral valve repair for patients suffering from the effects of MR in Europe. The MitraClip(R) system is currently in late stage clinical trials in the United States.
About Mitral Regurgitation
MR is the most common type of heart valve insufficiency in the United States and Europe, affecting millions of people worldwide. Significant MR affects more than eight million people in the US and Europe, the majority of which have FMR. There are more than 600,000 new diagnoses of significant MR each year in the US and Europe; however, only 20 percent of these patients undergo surgery each year. Many higher risk surgical patients and non-surgical patients continue to be affected by the chronic volume overload caused by MR, which requires the heart to work harder, and may ultimately lead to heart failure.
About the MitraClip(R) Procedure
Mitral repair with Evalve’s MitraClip(R) device is performed by physicians in the catheterization laboratory. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine. In addition to improving blood flow through the heart, the procedure may also relieve symptoms such as fatigue and shortness of breath that often affect patients with significant MR. After treatment, patients generally recover quickly. The MitraClip(R) device may improve quality of life and may help MR patients avoid or delay surgery, having preserved surgical options (valve repair or replacement) should surgery become necessary.
About Evalve, Inc.
Cofounded in 1999 by The Foundry and Dr. Fred St. Goar, Evalve, Inc., headquartered in Menlo Park, Calif., and has developed a proprietary system which enables percutaneous repair of cardiac valves. The company’s initial products are intended to reduce the risks, trauma and costs associated with current open, arrested heart surgical options. For more information about Evalve, Inc., and for an animated explanation of the procedure using the MitraClip(R) device, visit www.evalveinc.com. The MitraClip(R) system is currently undergoing clinical evaluation in the United States and Canada. Enrollment is ongoing in the REALISM study in the US, which allows EVEREST investigators and their patients continued access to the MitraClip(R) therapy during the PMA phase. The MitraClip(R) system is commercially distributed in Europe.
MitraClip(R) and Evalve are registered trademarks of Evalve, Inc.
Media Contact: Heather Harper Edelman +1-415-486-3233 office +1-415-533-1001 mobile Heather.Harper@edelman.com
Source: Evalve, Inc.
Heather Harper of Edelman, office, +1-415-486-3233, mobile, +1-415-533-1001, Heather.Harper at edelman.com, for Evalve, Inc.
Related Press Releases
MitraClip(R) Therapy Data Demonstrate Significant Left Ventricular Reverse Remodeling in Patients With Sustained Reduction of Mitral RegurgitationSeptember 21st, 2009 SAN FRANCISCO -
- 12-Month Data Presented at TCT 2009 Show Significant Improvement in Left Ventricular Function with no Change in Annular Dimensions
Sustained reduction of mitral regurgitation following mitral valve repair with the MitraClip(R) system in patients with degenerative mitral regurgitation (DMR) or functional mitral regurgitation (FMR) led to heart function improvements, according to 12-month data from a subset of the initial registry cohort of the EVEREST (Endovascular Valve Edge-to-Edge REpair STudy) studies presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco. The data were presented today by Scott Lim, M.D., interventional cardiologist at the University of Virginia Medical Center and one of the EVEREST trial investigators.
Data Show Long-Term Mechanical Integrity of MitraClip(R) and Complete Healing Following Implantation of the Device for Mitral Valve RepairSeptember 21st, 2009 SAN FRANCISCO -
- Results of Histopathology and Mechanical Integrity Analysis of MitraClip(R) Devices Presented at TCT 2009
The mechanical integrity of the MitraClip(R) device for repair of the mitral valve was maintained for up to five years and with complete healing, according to a subset of data from the EVEREST (Endovascular Valve Edge-to-Edge REpair STudy) study presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco. The data also show complete fibrous encapsulation of the MitraClip device with organized, endocardial tissue growth demonstrating complete healing and incorporation of the implant within the native mitral valve.
Guided Delivery Systems, Inc. Successfully Treats First Patient with Mitral RegurgitationSeptember 15th, 2009 SANTA CLARA, California -
Guided Delivery Systems, Inc. ("GDS") announced the first successful percutaneous implantation of the GDS Accucinch(R) System for mitral valve repair.
Ongoing Progress of MitraClip(R) Therapy Highlighted at TCT 2009September 14th, 2009 MENLO PARK, California -
- European Commercial Pace Continues to Grow with 200 Patients Treated
- Evalve Reaches U.S. Clinical Trial Milestone
The upcoming Transcatheter Cardiovascular Therapeutics (TCT) Conference, to take place in San Francisco from September 21-25, will serve as a backdrop for the presentation of EVEREST registry clinical results of the MitraClip(R) therapy for patients with mitral regurgitation (MR).
MitraClip(R) Therapy Introduced in AustriaSeptember 8th, 2009 MENLO PARK, California -
- Use of the MitraClip(R) System Continues to Expand in Europe
Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, today announced treatment of the first group of patients with the MitraClip(R) system at the Elisabethinen Krankenhaus, Linz, Austria. The MitraClip(R) system is the only medical device commercially available in the European Union which provides a non-surgical mitral valve repair option for patients suffering from the effects of functional and degenerative mitral regurgitation (MR).
First Swedish Patients Receive MitraClip(R) TherapyAugust 23rd, 2009 MENLO PARK, California -
- Use of the MitraClip(R) System Continues to Expand in Europe
Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, today announced treatment of the first group of patients with the MitraClip(R) system at the Karolinska University Hospital in Solna, Stockholm, Sweden. The MitraClip(R) system is the only medical device commercially available in the European Union which provides a non-surgical mitral valve repair option for patients suffering from the effects of functional and degenerative mitral regurgitation (MR).
EVEREST Data Demonstrates Acute Reduction of Mitral Regurgitation Without Procedural Mortality in Patients Treated With the MitraClip(R) TherapyAugust 12th, 2009 MENLO PARK, California -
- Durability Observed in Both Functional and Degenerative MR Patient Populations
Data published today in the Journal of the American College of Cardiology (JACC) indicates that percutaneous valve repair with the MitraClip(R) therapy can reduce acute mitral regurgitation (MR) with sustained freedom from death, surgery or recurrent MR in a substantial proportion of functional and degenerative MR patients. The published data is from the initial cohort of 107 registry patients treated in the EVEREST (Endovascular Valve Edge-to-Edge REpair STudy) trial, sponsored by Evalve, Inc.
MitraClip(R) Therapy Data Demonstrate Clinical Benefit in High-Risk Patients With Mitral RegurgitationMay 19th, 2009 BARCELONA, Spain - EVEREST High-Risk Registry Data Show Improved Symptomatic Status, Cardiac Function and Reduced rate of Hospitalization for Congestive Heart Failure in both Functional and Degenerative MR Patient Populations
Results show percutaneous mitral repair using the MitraClip(R) system in symptomatic high-risk surgical patients with either functional mitral regurgitation (FMR) or degenerative mitral regurgitation (DMR) improves patient clinical status. The results from the 78 patient EVEREST II High Risk Registry demonstrated improvement in left ventricular function and reduced hospitalization for congestive heart failure for both MR groups at twelve months.
First Patients Enrolled in the Access-Europe Study of The MitraClip(R) TherapyApril 5th, 2009 MENLO PARK, California - European Post Market Observational Study Intended to Collect Data to Demonstrate the Clinical and Health Economic Benefits of the MitraClip(R) Therapy for Patients with Mitral Regurgitation
Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today the first enrollment in the ACCESS-Europe study, a post-market observational study of the MitraClip(R) therapy in Europe. The MitraClip(R) system is the first commercially available treatment option for non-surgical mitral valve repair for patients suffering from the effects of functional and degenerative mitral regurgitation (MR).
MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow UpMarch 27th, 2009 ORLANDO, Florida - EVEREST High-Risk Registry Data Shows Improved Symptomatic Status and
Cardiac Function in Functional MR Patients Treated with the MitraClip(R)
System
Percutaneous mitral valve repair using the MitraClip(R) system in
symptomatic high-risk surgical patients with functional mitral regurgitation
(FMR) improves patient clinical status, and left ventricular function,
according to 12-month data from the high-risk registry arm of the EVEREST II
(Endovascular Valve Edge-to-Edge REpair STudy) study presented today at the
58th Annual Scientific Session of the American College of Cardiology (ACC) i2
Summit Scientific Sessions. As the most common type of heart valve disease, MR affects more than four
million people in the United States, the majority of which have FMR.
Related News
Meditation key to treating female incontinenceMay 5th, 2009 WASHINGTON - Meditation or cognitive therapy may be an effective management strategy to control the frequent urge to urinate among women, according to a study. Loyola University Health System (LUHS) have employed cognitive therapy to treat overactive bladders.
NASA delays launch of space shuttle DiscoveryAugust 28th, 2009 WASHINGTON - NASA managers have postponed the launch of space shuttle Discovery to allow engineers more time to develop plans for resolving an issue with a valve in the shuttle's main propulsion system. Launch now is targeted for no earlier than 11:59 p.m.
Statins cut stroke risk by a fifthApril 15th, 2009 LONDON - Cholesterol-lowering statins can decrease the risk of strokes by about a fifth, a new study has claimed. The research reviewed some 24 studies, and found lower cholesterol levels were associated with a reduced risk of stroke.
Meditating your way to better bladder controlMay 5th, 2009 WASHINGTON - After nine years of living in constant fear of venturing out of her house, 53-year-old Anna Raisor approached physicians for alternative measures to treat embarrassing accidental or involuntary loss of urine. Physicians of the Loyola University Health System (LUHS) in Chicago enrolled Raisor in a clinical trial using cognitive therapy to manage her overactive bladder.
Spirituality helps teens cope with chronic illnessJanuary 8th, 2009 WASHINGTON - Spirituality may help teens cope with chronic illness, which can make life a living hell. Two recent studies, conducted by Michael Yi and Sian Cotton in University of Cincinnati (UC), investigated how adolescents with inflammatory bowel disease (IBD) may use spirituality to cope with illness.
China orders halt to treating Internet addicts with electric shock therapyJuly 14th, 2009 China stops shock therapy for Internet addictsBEIJING — China's Health Ministry has ordered a hospital to stop using electric shock therapy to cure youths of Internet addiction, saying there was no scientific evidence it worked. Linyi Mental Health Hospital in eastern Shandong province used the treatment as part of a four-month program that has so far treated nearly 3,000 youths, the China Youth Daily newspaper has reported, citing the psychiatrist who runs it, Yang Yongxin.
Ecstasy could help those suffering from stress after traumaMarch 9th, 2009 LONDON - Ecstasy may help sufferers of post-traumatic stress deal with painful memories more effectively by encouraging a feeling of safety, according to a new study. Studies have shown that exposure therapy - where the patient recalls traumatic experiences or is exposed to stressful situations repeatedly, can be effective in relieving patients with post-traumatic stress disorder (PTSD) and other anxious conditions.
Weight loss can cure obstructive sleep apneaFebruary 8th, 2009 LONDON - Losing weight could be the most effective way of reducing obstructive sleep apnea or OSA symptoms and associated disorders, says a new study. Weight loss may not be a new miracle pill or a fancy high-tech treatment, but it is an exciting therapy for sufferers of OSA both because of its short- and long-term effectiveness and for its relatively modest price tag.
China bans controversial electric-shock therapy for Internet addictsJuly 14th, 2009 BEIJING - The Chinese Health Ministry has ordered a halt to the controversial electroshock therapy, which it was useing to treat teen Internet addicts. The ministry has said that the therapy, which was administered by a clinic in Linyi, Shandong province, is not safe.
Nightmares? Try dream therapyJuly 30th, 2009 Indo-ASIAN NEWS SERVICE
LONDON - Dream therapy could show a way out of recurring nightmares, according to a new study. The previously discredited approach is drawing the interest of clinicians, because it can treat nightmares by training the victims to dream lucidly, so they can consciously wake up.
